
==== Front
Mol Imaging Biol
Mol Imaging Biol
Molecular Imaging and Biology
1536-1632
1860-2002
Springer International Publishing Cham

38942967
1929
10.1007/s11307-024-01929-7
Research Article
Pilot Evaluation of S-(3-[18F]Fluoropropyl)-d-Homocysteine and O-(2-[18F]Fluoroethyl)-d-Tyrosine as Bacteria-Specific Radiotracers for PET Imaging of Infection
http://orcid.org/0000-0003-2086-8731
Betts Helen M. helen.betts@nottingham.ac.uk

12
http://orcid.org/0000-0003-3344-7514
Luckett Jeni C. 3
http://orcid.org/0000-0002-2250-1397
Hill Philip J. 4
1 grid.415598.4 0000 0004 0641 4263 Department of Nuclear Medicine, Nottingham University Hospitals NHS Trust, Queen’s Medical Centre, Nottingham, NG7 2UH UK
2 grid.4563.4 0000 0004 1936 8868 School of Medicine, University of Nottingham, Queen’s Medical Centre, Nottingham, NG7 2UH UK
3 https://ror.org/01ee9ar58 grid.4563.4 0000 0004 1936 8868 School of Life Sciences, University of Nottingham, Biodiscovery Institute, University Park, Nottingham, NG7 2RD UK
4 https://ror.org/01ee9ar58 grid.4563.4 0000 0004 1936 8868 School of Biosciences, University of Nottingham, Sutton Bonington Campus, Sutton Bonington, LE17 5RD UK
28 6 2024
28 6 2024
2024
26 4 704713
5 2 2024
12 6 2024
14 6 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Purpose

There is currently no ideal radiotracer for imaging bacterial infections. Radiolabelled d-amino acids are promising candidates because they are actively incorporated into the peptidoglycan of the bacterial cell wall, a structural feature which is absent in human cells. This work describes fluorine-18 labelled analogues of d-tyrosine and d-methionine, O-(2-[18F]fluoroethyl)-d-tyrosine (d-[18F]FET) and S-(3-[18F]fluoropropyl)-d-homocysteine (d-[18F]FPHCys), and their pilot evaluation studies as potential radiotracers for imaging bacterial infection.

Procedures

d-[18F]FET and d-[18F]FPHCys were prepared in classical fluorination-deprotection reactions, and their uptake in Staphylococcus aureus and Pseudomonas aeruginosa was evaluated over 2 h. Heat killed bacteria were used as controls. A clinically-relevant foreign body model of S. aureus infection was established in Balb/c mice, as well as a sterile foreign body to mimic inflammation. The ex vivo biodistribution of d-[18F]FPHCys in the infected and inflamed mice was evaluated after 1 h, by dissection and gamma counting. The uptake was compared to that of [18F]FDG.

Results

In vitro uptake of both d-[18F]FET and d-[18F]FPHCys was specific to live bacteria. Uptake was higher in S. aureus than in P. aeruginosa for both radiotracers, and of the two, higher for d-[18F]FPHCys than d-[18F]FET. Blocking experiments with non-radioactive d-[19F]FPHCys confirmed specificity of uptake. In vivo, d-[18F]FPHCys had greater accumulation in S. aureus infection compared with sterile inflammation, which was statistically significant. As anticipated, [18F]FDG showed no significant difference in uptake between infection and inflammation.

Conclusions

d-[18F]FPHCys uptake was higher in infected tissues than inflammation, and represents a fluorine-18 labelled d-AA with potential to detect a S. aureus reference strain (Xen29) in vivo. Additional studies are needed to evaluate uptake of this radiotracer in clinical isolates.

Supplementary Information

The online version contains supplementary material available at 10.1007/s11307-024-01929-7.

Keywords

PET
Fluorine-18
Bacterial infection
S. aureus
P. aeruginosa
d-amino acids
http://dx.doi.org/10.13039/501100000265 Medical Research Council MC_PC_17173 Betts Helen M. issue-copyright-statement© World Molecular Imaging Society 2024
==== Body
pmcIntroduction

Bacterial infection and antimicrobial resistance are recognised as global threats to human health [1, 2]. The aging population coupled with surgical advances means that increasing numbers of patients are undergoing elective surgery—such as joint replacements, vascular grafts and cardiac implants—and there has been a concomitant increase in the number of hospital-acquired infections [3, 4]. Approximately 800,000 hospital-acquired surgical site infections (SSI) were reported in an EU/EAA survey of 2011–12, leading to 16,000 deaths [5]. The impact of infection for patients ranges from the need to have repeat surgery, leading to immobilisation and weeks’-long hospital stays, to (particularly in the case of vascular graft infections) death [5, 6]. To ensure that patients receive optimal treatment when infection is suspected, and to responsibly manage antibiotic use, rapid, accurate diagnosis of infection is critical.

When patients experience complications post-surgery, conclusive diagnosis of infection is not straightforward. Biopsy sampling from a surgical site is invasive, subject to sampling errors and potential contamination, is dependent on the site being accessible, and fails to account for any heterogeneity [7]. Non-invasive imaging techniques MRI and CT provide limited anatomical clues to the presence of an infection, but these physical changes are often slow to manifest leading to delay in diagnosis. Furthermore, the structural abnormalities observed by these methods can be a result of sterile inflammatory processes (such as prosthetic joint loosening) [8, 9]. There are difficulties in distinguishing active infection from sterile inflammation when using existing clinical radiotracers for positron emission tomography (PET) such as 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) [10], or single photon emission computed tomography (SPECT), such as [111In]In-oxine or [99mTc]Tc-HMPAO labelled white blood cells [11]. Although these radiotracers can be used to detect certain infections with high sensitivity, their uptake is primarily determined by the immune response to infection, and is not specific to the bacteria. Use of these radiotracers is particularly challenging in vulnerable patients who are immune compromised, or have cancer [7, 10–12].

PET imaging using a bacteria-specific radiotracer would provide an ideal technique for diagnosing bacterial infection, as well as have potential to monitor the efficacy of antibiotic treatments. Recent developments towards this goal include probes based on sugar alcohols [13, 14], polysaccharides [15, 16], muramic acid [17] and antibiotics [18], amongst others [19]. First steps in patient imaging have been made with the research radiotracers p-aminobenzoic acid ([11C]PABA), [11C]trimethoprim and [18F]fluorodeoxysorbitol ([18F]FDS). PABA is a substrate of bacterial folate synthesis and its radiolabelled derivative accumulates in both Gram positive and Gram negative bacteria in all growth phases [20–22]. First in human studies, however, showed rapid metabolism in plasma [23]. [11C]Trimethoprim is a radiolabelled antibiotic that has recently shown promising results in patients with confirmed bacterial infections, including those with antibiotic-resistant strains. One of its limiting features for routine use, however, is its short lived carbon-11 radiolabel (t1/2 = 20 min) [18]. [18F]FDS is selectively metabolised in Enterobacteriaceae such as E. coli and can identify these select pathogens by PET in patients, but it is not able to detect Gram positive bacteria such as S. aureus [24, 25]. Clinical results of bacteria-specific fluorine-18 radiotracers that can accumulate in Gram positive bacteria are yet to be reported.

Recently, d-enantiomers of amino acids (AAs) have emerged as molecules of interest for bacteria-specific imaging. d-AAs are an essential component of bacterial peptidoglycan cell walls, a structural feature which is absent in human cells, whereas d-AAs have limited uses in humans. Notably, d-serine is synthesised by racemase in the human brain and is as co-agonist of the NMDA receptor [26]. The mirror-image l-AAs are, however, prevalent as they are required by human protein synthesis mechanisms. The carbon-11 labelled d-AAs d-methionine (d-[11C]Met) [27, 28], d-alanine (d-[11C]Ala) [29] and d-glutamine (d-[11C]-Gln) [30] have been evaluated as potential bacteria-specific radiotracers, targeting the bacterial cell wall. These radiotracers show specific accumulation in various metabolically active bacteria, but all are limited by the short-lived nature of carbon-11. A fluorine-18 (t1/2 = 110 min) labelled d-AA would provide a practical alternative that could be used in hospitals without a local cyclotron. Recently, 3,3,3-[18F]trifluoromethyl-d-alanine (d-[18F]CF3-Ala) was reported with this goal in mind [31]. d-[18F]CF3-Ala showed highest accumulation in Gram negative bacteria, especially E. Coli. Herein, we present results of two fluorine-18 labelled d-AAs as potential bacteria-specific radiotracers; O-(2-[18F]fluoroethyl)-d-tyrosine (d-[18F]FET) and S-(3-[18F]fluoropropyl)-d-homocysteine, (d-[18F]FPHCys) (Scheme 1).Scheme 1 Radiosynthesis of d-[18F]FET and d-[18F]FPHCys. Radioactivity yields of purified product are given, not corrected for decay.

Materials and Methods

Chemistry and Radiochemistry

The non-radioactive reference materials d-[19F]FET and d-[19F]FPHCys, and their radiolabelling precursors were prepared using modified literature procedures for l-enantiomers (Scheme 1) [32, 33]. d-[18F]FET and d-[18F]FPHCys were radiolabelled using classical nucleophilic substitution-deprotection reactions. Full experimental details and characterisation data are presented in the Electronic Supplementary Material (ESM).

In VitroBacteria Uptake and Blocking Studies

S. aureus (Xen29) or P. aeruginosa (PA01, Lausanne) were grown to mid-log phase in Ham’s F12 buffer for SILAC (ThermoFisher). Cells were collected by centrifugation and re-suspended in 10% glycerol/phosphate buffered saline (PBS). Aliquots (20 µL, 1 × 107 CFU) were stored at -80 °C until the experiment, then re-suspended in F12 buffer (20 µL). Prior to use, purified d-[18F]FPHCys or d-[18F]FET (80 µL, mean 32 kBq, range 25–48 kBq) was diluted (1:9 v/v) with F12 buffer, and added to the thawed aliquot. The final concentration of EtOH was < 0.8%. The mixtures were incubated at 37 °C and at 30, 60, 90 and 120 min, centrifuged (12,000 rpm, 5 min), supernatant separated, and washed with PBS (2 × 100 µL). Counts associated with the pellet and washings were recorded. Heat-killed bacteria (90 °C, 30 min, verified by lack of growth on CFU analysis) were used as controls [27]. Blocking studies were performed for d-[18F]FPHCys at 120 min, using the radiotracer (70 µL), bacteria in F12 (20 µL) and non-radioactive d-[19F]FPHCys (10 µL, dissolved in F12) to give final concentrations of 0.01–5 mM.

Animal Models

All applicable institutional and national guidelines for the care and use of animals were followed. All animal experiments were approved by the University of Nottingham Animal Welfare and Ethical Review Board and performed under project licence PP5768261 and personal licences granted by the UK Home Office. ARRIVE guidelines were followed. The procedures were classed as moderate in severity.

Subcutaneously implanted Cytodex beads (Cytodex-1 microcarrier beads, particle size 60–87 µm, Sigma) were used as a model foreign body. The beads were hydrated in PBS, then autoclaved. Female Balb/c mice (mean 21.6 g, range 19–24 g) were prepared with subcutaneous injection of the beads on the flank, either co-injected with S. aureus Xen29 (1 × 105 CFU), or alone for sterile inflammation. Mice were kept in IVC cages with access to food and water ad libitum, and were weighed and monitored daily. The infection was established for 4 days prior to the biodistribution study. The S. aureus group was imaged daily using an IVIS Spectrum In vivo imaging system (Perkin Elmer), and immediately prior to the biodistribution study. Mice were anaesthetised under isoflurane (4% induction; 1.5% maintenance) during image capture, for 30 s acquisition with small (4) binning and open filter settings. Note that S. aureus Xen29 contains the Photorhabdus luminescens LuxABCDE operon as a single chromosome insertion, thus the bioluminescence is not lost over time due to bacterial replication.

Ex Vivo Biodistribution Study

For [18F]FDG, the biodistribution study was performed in mice with inflammation (n = 6) and S. aureus infection (n = 6). For d-[18F]FPHCys the study was performed in mice with inflammation (n = 4) and S. aureus infection (n = 8). The radiotracer was injected via tail vein (mean 1.9 MBq, range 0.8–3.0 MBq), and after 1 h, animals were sacrificed by sodium pentobarbital and organs of interest collected in pre-weighed vials. Samples were analysed using an automated gamma counter (Hidex). Data is expressed as percent injected dose per gram of tissue (%ID/g), decay corrected to injection time. The injected dose (in cpm) was calculated from a calibration curve that related the measured reading on the dose calibrator (syringe pre- and post-injection, in MBq) to the gamma counter (in cpm). Figures were prepared using Graphpad Prism, and show the mean with standard error (SEM) bars.

Immunohistochemistry

Samples of sites of infection and inflammation were fixed in 10% formalin-saline solution, and processed for paraffin embedding. Sections (8 µm) were taken and fixed to microscope slides. Sections were processed and stained with haematoxylin and eosin according to standard protocols [34], and visualised using a Hamamatsu NanoZoom slide scanner. Immunohistochemistry was performed on parallel sections, which were rehydrated and assessed for S. aureus colonisation by epitope retrieval using trypsin (10 µg/mL) at 37 °C for 10 min. Tissues were washed with PBS and pre-blocked at 37 °C using bovine serum (5% v/v) for 1 h, then incubated with primary rabbit antibody to S. aureus (BioRad 0300–0084, diluted 1:500) for 2 h at 37 °C. After washing with PBS (3 x), tissue sections were incubated with a secondary anti-rabbit Alexa 555. After washing in PBS (3 x), the sections were incubated in DAPI (300 nm) for 10 min. The sections were again washed in PBS (3 x) and mounted with Fluoromount (Sigma Aldrich). Images were acquired using a Zeiss confocal CD7 imager.

Statistical Analysis

Statistical analysis was performed using Microsoft Excel. Significance was determined by the two unpaired variables t-test, assuming equal variance. The validity of this assumption was checked using Levene’s test.

Results

Radiochemistry

d-[18F]FET and d-[18F]FPHCys were prepared from their respective tosylate precursors by classic nucleophilic 18F-fluorination-deprotection reactions (Scheme 1). By using biocompatible HPLC eluents (EtOH-aqueous sodium phosphate) the purified radiotracers could be used directly in the in vitro and in vivo studies by dilution in F12 medium or PBS without further reformulation. Stability tests in EtOH-sodium phosphate formulation by HPLC indicated no decomposition for at least 6 h.

In Vitro Bacterial Uptake and Blocking Studies

d-[18F]FPHCys showed increasing uptake in live S. aureus over 2 h (Fig. 1a). At 2 h, the mean uptake reached 36 Bq/106 cells, compared with < 1 Bq/106 cells in heat-killed bacteria at the same time point. d-[18F]FPHCys uptake in P. aeruginosa was lower (Fig. 1b), reaching 4 Bq/106 cells at 2 h, and 1 Bq/106 cells in heat-killed P. aeruginosa. The difference in mean uptake between live and heat-killed bacteria at 2 h was significant in both S. aureus and P. aeruginosa (p = 0.004 and p = 0.002 respectively). Data expressed as percentage of applied radioactivity associated with the cells are presented in S5, in the ESM.Fig. 1 Uptake of d-[18F]FET and d-[18F]FPHCys in (a) S. aureus (b) in P. aeruginosa. NB. d-[18F]FET uptake in heat-killed bacteria was performed only at the final time point (2 h). This data point has been slightly offset from 120 min for clarity. Where SEM markers are not visible, the marker falls within the data point. (c) Blocking study of d-[18F]FPHCys uptake in S. aureus and P. aeruginosa, where non-radiolabelled d-FPHCys was applied. Graph shows mean with error bars of SEM.

d-[18F]FET showed similarly increasing uptake over 2 h in S. aureus, up to 16 Bq/106 cells in live bacteria compared with < 1 Bq/106 cells in heat-killed S. aureus (Fig. 1a). This difference in mean was statistically significant (p = 0.004). d-[18F]FET uptake in P. aeruginosa was lower than in S. aureus, reaching 2 Bq/106 cells in live, and 1 Bq/106 cells in heat-killed bacteria, however this was not significant (p = 0.11) (Fig. 1b).

Blocking experiments were performed on d-[18F]FPHCys uptake to establish the specificity of the incorporation, by addition of d-FPHCys (Fig. 1c). In both S. aureus and P. aeruginosa, the uptake of d-[18F]FPHCys was blocked in a concentration dependent manner.

Animal Models

Representative images of the S. aureus bioluminescence in a single animal are shown in Figs. 2a-e. Figure 2f shows a mouse implanted with sterile Cytodex beads, confirming no light output in the absence of S. aureus.Fig. 2 Representative bioluminescence images of mouse with Cytodex beads implanted. (a-e) Same mouse with S. aureus infection, images on days 0, 1, 2, 3, and 4. (f) Mouse with Cytodex bead implant (inflammation) only.

Ex Vivo Biodistribution Studies

d-[18F]FPHCys showed higher mean uptake in the S. aureus infection site compared with the inflammation group (p = 0.016, Fig. 3a). As expected from the non-specific radiotracer [18F]FDG, there was no evidence of a difference in the means in the infection and inflammation sites (Fig. 3b) [10].Fig. 3 Radiotracer uptake in mouse model of S. aureus infection site compared with a sterile inflammation site. (a) d-[18F]FPHCys (b) [18F]FDG.

Whole body ex vivo biodistribution of [18F]FDG and d-[18F]FPHCys in mice with infection and inflammation is shown in Fig. 4a and 4b respectively. The uptake of each radiotracer in the S. aureus infection group and the inflammation group is displayed separately. Considering each radiotracer separately, there were no statistically significant differences between the mean uptake in any of the organs in the infection or inflammation groups. The difference in means of pancreatic uptake for d-[18F]FPHCys between the two groups was not significant (p = 0.21). Full statistical analyses are presented in Tables S1 and S2, in the ESM.Fig. 4 Whole body ex vivo biodistribution in S. aureus infection and inflammation models (a) [18F]FDG (b) d-[18F]FPHCys.

Uptake of d-[18F]FPHCys was highest in the pancreas, kidneys and liver, akin to biodistribution data previously reported for this radiotracer in mice for cancer investigations [33]. The prior studies also confirmed good stability of d-[18F]FPHCys in vivo and that the radioactivity found in the pancreas was > 95% parent compound at 1 h post-injection. The radiotracer was rapidly cleared [33].

Immunohistochemistry

Sections of mouse skin from a sterile inflammation site and an S. aureus infection site were stained with hematoxylin and eosin (left panel), and anti-Staphylococcus antibody (right panel) (Fig. 5a and 5b respectively).Fig. 5 H&E staining of section of mouse skin (left) and visualisation of S. aureus by detection with anti-Staphylococcus antibody (green, right) for (a) sterile inflammation site (b) S. aureus infection site. Magnified sections showing infiltration of immune cells in (c) sterile inflammation with Cytodex bead (d) S. aureus infection with Cytodex bead. Asterisks indicate clusters of S. aureus. Arrow indicates S. aureus in muscle layer.

The Cytodex beads were surrounded by an infiltration of immune cells in both inflammation and infection. The anti-Staphylococcus stain highlights S. aureus (green) in the infected section only. The staining pattern indicates clusters of S. aureus (asterisks) as well as a lateral development of infection at the basement of the muscle layer (arrow).

Discussion

The choice of fluorinated d-AAs to investigate was determined by a two factors: (1) feasibility of radiosynthesis from [18F]fluoride and (2), likelihood that the d-AA would be incorporated in the bacterial peptidoglycan cell wall, to create the desired contrast between bacteria and human inflammatory cells. 18F-Fluorinated AAs can be difficult to access by nucleophilic 18F-fluorination radiochemistry [35] and we therefore selected two AA candidates with established synthetic routes. The l-tyrosine (Tyr) derivative l-[18F]FET is clinically advanced and is a useful tool for predicting and monitoring treatment response in patients with glioma [36]. The methionine (Met) analogue, [18F]FPHCys (as both l- and d-enantiomers) has been evaluated before in cancer imaging [33]. Neither of the d-enantiomers has been evaluated previously for bacterial infection imaging. During the course of this work, d-[11C]Met was reported as a promising candidate for bacterial infection imaging, and thus evaluation of its fluorinated analogue d-[18F]FPHCys was of interest [27]. d-[11C]Alanine (d-[11C]Ala) was also described recently, showing good uptake across a panel of bacteria, [29, 37] but although accessible from [18F]fluoride, we discounted 3-[18F]fluoro-d-Ala because the L-enantiomer rapidly defluorinates in vivo [38]. Few other AAs are readily prepared by late-stage radiofluorination.

Exogenous d-AAs are appended to the muropeptides of peptidoglycan by transpeptidase enzymes [39]. Both d-Tyr and d-Met are substrates of these enzymes, which are known to tolerate a variety of unnatural side chains [40–43]. Modification of d-Met and d-Tyr with fluorine-18 was therefore reasonable.

Radiosyntheses of both d-[18F]FET and d-[18F]FPHCys were achieved as one-pot, two-stage reactions that are amenable to automation, which would be essential for future clinical translation. Furthermore, in both cases, the desired chiral centre was already established in the precursor, and a challenging chiral induction or enantiomer separation were not required in the radiolabelling procedure.

In vitro uptake studies confirmed that both d-[18F]FET and d-[18F]FPHCys became associated with live bacteria but not with heat-killed bacteria, indicating that detection of active infection was feasible. The in vitro uptake of d-[18F]FPHCys in S. aureus was higher than observed by Stewart for d-[11C]Met (ca. 20 Bq/106 cells) after 2 h [44], and similar as percentage uptake (ca. 2%) to that observed by Neumann for d-[14C]Met, although different S. aureus strains were used (Xen29 vs ATCC 12600, although Xen29 is a derivative of ATCC 12600) [27, 45, Fig S5 ESM]. Since d-[18F]FPHCys is an unnatural analogue of the parent d-Met, we were encouraged that its activity in vitro showed at least comparable uptake to the parent under similar assay conditions. Our studies revealed approximately twofold higher-uptake for d-[18F]FPHCys than d-[18F]FET in both S. aureus and P. aeruginosa. For this reason, we selected of d-[18F]FPHCys for in vivo studies.

d-[18F]FPHCys was next evaluated in vivo. Injection of the Cytodex beads and S. aureus for the infection group allowed us to assess a clinically relevant site of co-existing infection and inflammation. S. aureus is the most commonly found pathogen in SSI and accounted for around 18% of all SSI in an EU-wide study [8, 46, 47]. In addition to its prevalence in SSI, S. aureus is a clinically challenging bacterium which has increasing resistance to antimicrobials, making it a key pathogen for focus in research [48]. The bioluminescent S. aureus allowed visualisation of metabolically active S. aureus in the animals prior to the biodistribution study. The bioluminescent signal is proportional to the number of metabolically active bacteria present (although factors such as hypoxia and depth effects in imaging prevent accurate calculations of bacterial number in vivo from this data). IHC analysis of the infected and inflamed skin sections (after radioactive decay) confirmed leucocyte infiltration in both infection and inflammation sites. By day 4, S. aureus infection would have become established and akin to a clinical infection of a foreign body, and is likely to have begun biofilm formation.

In the biodistribution study, d-[18F]FPHCys showed increased uptake in S. aureus infection site versus inflammation site, which was statistically significant. Although direct comparison of d-[18F]FPHCys uptake with d-[11C]Met, d-[11C]Ala and [18F]CF3-d-Ala would be informative, this is challenging due to the differing characteristics of the animal models used here and in previously reported studies [27, 29, 31]. The ex vivo analysis of radiotracer uptake (as percent injected dose per gram) in the infection site appears generally lower for d-[18F]FPHCys than for other reported d-AAs. A comparison of the performance of d-AAs in vivo is provided in the ESM (Table S3). A number of reasons may account for this. First, the S. aureus infection model used in the present study mimics an established infection, which has been allowed to develop over 4 days. S. aureus infections are known to form biofilms [49], potentially creating a barrier to uptake of a blood circulating radiotracer compared with an acute S. aureus infection, in which bacteria were injected a few hours before an in vivo study. Second, the quantity of bacteria present in the model infection site is an important factor. Typically, acute soft tissue infections are associated with bacterial burden of 108 CFU/mL, but it has been suggested that 105 CFU/mL is a promising threshold for imaging chronic or partially treated infection [7]. Our initial inoculant contained 1 × 105 CFU per infection site, although the burden in the mice at day 4 was not determined. Both these features of our model provide clinically relevant and challenging conditions for a potential radiotracer, as would be faced in a clinical scenario. Future evaluation of d-[18F]FPHCys in additional animal models of infection, as well as reducing bacterial load further would be informative.

There was no significant difference in [18F]FDG uptake in sites of S. aureus infection compared with sterile inflammation in our animal model. This was expected because [18F]FDG uptake for infection imaging primarily represents increased glycolytic activity of inflammatory cells, although [18F]FDG does accumulate in bacteria [10, 50]. This assertion was borne out in this study by the inability of [18F]FDG to distinguish the S. aureus infection from inflammation, and supports the conclusion that d-[18F]FPHCys is specifically targeting the bacteria. Furthermore, [18F]FDG uptake in the inflammation and infection sites in our animal model (ca. 2 %ID/g) was lower than that observed for [18F]FDG in the murine myositis model used for evaluation of other d-AA radiotracers (ca. 4 %ID/g) [27, 29, Table S3]. This supports our conclusion that the lower accumulation of d-[18F]FPHCys is, at least in part, likely a result of different characteristics of the animal model.

A potential limitation of d-[18F]FPHCys, like other radiolabelled d-AAs, is that its uptake requires the bacteria to be in a metabolically active state. For all radiotracers targeting bacterial metabolism, a challenge remains for imaging infection sites that contain populations of quiescent cells, such as during antibiotic treatment. For imaging in these scenarios, radiotracers with uptake that is independent of growth phase may have an advantage. However, drug resistant strains can still be usefully visualised [22, 29].

In vivo metabolism of new radiotracers is also a key consideration. d-AAs are possible substrates of d-amino acid oxidase (DAAO), a flavoprotein that catalyses oxidative deamination of neutral d-AAs to form α-keto acids [26]. Although we did not test directly for DAAO metabolism in this study, previous studies in mice showed high metabolic stability of d-[18F]FPHCys in vivo [33]. One of the advantages of d-CF3-Ala is its stability against DAAO, and defluorination (unlike the mono-fluoro derivative, 3-[18F]fluoro-d-Ala) [31, 38].

Although S. aureus and P. aeruginosa are common culprits for SSI, d-[18F]FPHCys has not been evaluated across a full panel of pathogens, limiting the scope of this study.

d-[11C]Met has recently been evaluated in a first-in-human PET/MR study in healthy volunteers and patients with suspected joint infections [28]. While the results are promising in terms of both a favourable safety profile and an increase of d-[11C]Met uptake in suspected infections (although a gold standard for confirmed infection was lacking), an 18F-labelled analogue would have practical advantages for future application of d-AA imaging in patients with suspected infection. In our study, d-[18F]FPHCys distinguished S. aureus infection from sterile inflammation in a clinically relevant mouse model, paving the way for fluorinated d-AA imaging of S. aureus infections.

Conclusions

d-[18F]FPHCys is the first reported 18F-labelled d-AA able to distinguish S. aureus infection from inflammation in vivo, although further studies are needed to evaluate its uptake in clinical isolates. d-[18F]FPHCys offers practical advantages over d-AA radiotracers reported to date: it has a longer-lived fluorine-18 label versus the 11C-labelled d-AAs, and the chiral centre is established in the radiolabelling precursor and retained without racemisation during the radiosynthesis. Direct comparisons of d-[18F]FPHCys with d-[18F]CF3-Ala, which may complementarily detect Gram-positive and Gram-negative bacteria respectively, would be informative for future applications.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 658 KB)

Acknowledgements

We acknowledge Marian Meakin for technical assistance with the biodistribution study, and Prof Alan Perkins for helpful discussions and research support.

This work was funded by a UK Medical Research Council (MRC) Confidence in Concepts Award [MC_PC_17173].

Author Contributions

HMB conceived the project, acquired grant funding, undertook the synthetic chemistry, radiochemistry, in vitro experiments, in vivo experiment data collection, data analysis, statistical analysis, and drafted the manuscript. JCL contributed to the study design, provided materials for in vitro experiments, established the animal models (personal and project HO Licence holder), undertook the in vivo biodistribution, bioluminescence imaging, immunohistochemistry, and data analysis. PJH contributed to the study design and data analysis. All authors undertook critical review of the manuscript, and approved the final version.

Data Availability

Chemical synthesis and radiosynthesis data are available in the Electronic Supplementary Material accompanying this manuscript. Additional data is available from the corresponding author on reasonable request.

Declarations

Conflicts of Interest

The authors declare that they have no conflict of interest.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. World Health Organisation (n.d.) Antimicrobial resistance. https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance. Accessed 28 Jun 2022
2. Murray CJL Shunji Ikuta K Sharara F Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis Lancet 2022 399 629 655 10.1016/S0140-6736(21)02724-0 35065702
Murray CJL, Shunji Ikuta K, Sharara F et al (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399:629–65535065702 10.1016/S0140-6736(21)02724-0
3. Sabah SA Alvand A Price AJ Revision knee replacement for prosthetic joint infection: Epidemiology, clinical outcomes and health-economic considerations Knee 2021 28 417 421 10.1016/j.knee.2020.12.024 33500184
Sabah SA, Alvand A, Price AJ (2021) Revision knee replacement for prosthetic joint infection: Epidemiology, clinical outcomes and health-economic considerations. Knee 28:417–42133500184 10.1016/j.knee.2020.12.024
4. Erba PA Bartoli F Sollini M Alternative nuclear imaging tools for infection imaging Curr Cardiol Rep 2022 24 879 891 10.1007/s11886-022-01708-2 35696046
Erba PA, Bartoli F, Sollini M et al (2022) Alternative nuclear imaging tools for infection imaging. Curr Cardiol Rep 24:879–89135696046 10.1007/s11886-022-01708-2
5. Cassini A Plachouras D Eckmanns T Burden of six healthcare-associated infections on European population health: estimating incidence-based disability adjusted life years through a population prevalence-based modelling study PLOS Med 2016 10.1371/journal.pmed.1002150 27755545
Cassini A, Plachouras D, Eckmanns T et al (2016) Burden of six healthcare-associated infections on European population health: estimating incidence-based disability adjusted life years through a population prevalence-based modelling study. PLOS Med. 10.1371/journal.pmed.100215027755545 10.1371/journal.pmed.1002150
6. Lauri C Signore A Glaudemans AWJM Evidence-based guideline of the european association of nuclear medicine (EANM) on imaging infection in vascular grafts Eur J Nucl Med Mol Imaging 2022 49 3430 3451 10.1007/s00259-022-05769-x 35376992
Lauri C, Signore A, Glaudemans AWJM et al (2022) Evidence-based guideline of the european association of nuclear medicine (EANM) on imaging infection in vascular grafts. Eur J Nucl Med Mol Imaging 49:3430–345135376992 10.1007/s00259-022-05769-x
7. Ordonez AA Sellmyer MA Gowrishankar G Molecular imaging of bacterial infections: overcoming the barriers to clinical translation Sci Transl Med 2019 11 508 eaax8251 10.1126/scitranslmed.aax8251 31484790
Ordonez AA, Sellmyer MA, Gowrishankar G et al (2019) Molecular imaging of bacterial infections: overcoming the barriers to clinical translation. Sci Transl Med 11(508):eaax825131484790 10.1126/scitranslmed.aax8251
8. Signore A Sconfienza LM Borens O Consensus document for the diagnosis of prosthetic joint infections: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement) Eur J Nucl Med Mol Imaging 2019 46 971 988 10.1007/s00259-019-4263-9 30683987
Signore A, Sconfienza LM, Borens O et al (2019) Consensus document for the diagnosis of prosthetic joint infections: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement). Eur J Nucl Med Mol Imaging 46:971–98830683987 10.1007/s00259-019-4263-9
9. Sconfienza LM Signore A Cassar-Pullicino V Diagnosis of peripheral bone and prosthetic joint infections: overview on the consensus documents by the EANM, EBJIS, and ESR (with ESCMID endorsement) Eur Radiol 2019 29 6425 6438 10.1007/s00330-019-06326-1 31250170
Sconfienza LM, Signore A, Cassar-Pullicino V et al (2019) Diagnosis of peripheral bone and prosthetic joint infections: overview on the consensus documents by the EANM, EBJIS, and ESR (with ESCMID endorsement). Eur Radiol 29:6425–643831250170 10.1007/s00330-019-06326-1
10. Jamar F Buscombe J Chiti A EANM/SNMMI Guideline for 18F-FDG use in inflammation and infection J Nucl Med 2013 54 4 647 658 10.2967/jnumed.112.112524 23359660
Jamar F, Buscombe J, Chiti A et al (2013) EANM/SNMMI Guideline for 18F-FDG use in inflammation and infection. J Nucl Med 54(4):647–65823359660 10.2967/jnumed.112.112524
11. Signore A Jamar F Israel O Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline Eur J Nucl Med Mol Imaging 2018 45 1816 1831 10.1007/s00259-018-4052-x 29850929
Signore A, Jamar F, Israel O et al (2018) Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline. Eur J Nucl Med Mol Imaging 45:1816–183129850929 10.1007/s00259-018-4052-x
12. Bleeker-Rovers CP Vos FJ Van Der Graaf WTA Oyen WJG Nuclear medicine imaging of infection in cancer patients (With Emphasis on FDG-PET) Oncologist 2011 16 980 991 10.1634/theoncologist.2010-0421 21680576
Bleeker-Rovers CP, Vos FJ, Van Der Graaf WTA, Oyen WJG (2011) Nuclear medicine imaging of infection in cancer patients (With Emphasis on FDG-PET). Oncologist 16:980–99121680576 10.1634/theoncologist.2010-0421
13. Simpson SR Kesterson AE Wilde JH Imaging diverse pathogenic bacteria in vivo with 18F-fluoromannitol PET J Nucl Med 2023 64 809 815 10.2967/jnumed.122.264854 36522188
Simpson SR, Kesterson AE, Wilde JH et al (2023) Imaging diverse pathogenic bacteria in vivo with 18F-fluoromannitol PET. J Nucl Med 64:809–81536522188 10.2967/jnumed.122.264854
14. Ordonez AA Weinstein EA Bambarger LE A systematic approach for developing bacteria-specific imaging tracers J Nucl Med 2017 58 1 144 150 10.2967/jnumed.116.181792 27635025
Ordonez AA, Weinstein EA, Bambarger LE et al (2017) A systematic approach for developing bacteria-specific imaging tracers. J Nucl Med 58(1):144–15027635025 10.2967/jnumed.116.181792
15. Gowrishankar G Hardy J Wardak M Specific Imaging of Bacterial Infection Using 6″-18F-Fluoromaltotriose: A second-generation PET tracer targeting the maltodextrin transporter in bacteria J Nucl Med 2017 58 1679 1684 10.2967/jnumed.117.191452 28490473
Gowrishankar G, Hardy J, Wardak M et al (2017) Specific Imaging of Bacterial Infection Using 6″-18F-Fluoromaltotriose: A second-generation PET tracer targeting the maltodextrin transporter in bacteria. J Nucl Med 58:1679–168428490473 10.2967/jnumed.117.191452
16. Sorlin AM López-Álvarez M Rabbitt SJ Chemoenzymatic syntheses of fluorine-18-labeled disaccharides from [18F]FDG yield potent sensors of living bacteria in vivo J Am Chem Soc 2023 145 17632 17642 10.1021/jacs.3c03338 37535945
Sorlin AM, López-Álvarez M, Rabbitt SJ et al (2023) Chemoenzymatic syntheses of fluorine-18-labeled disaccharides from [18F]FDG yield potent sensors of living bacteria in vivo. J Am Chem Soc 145:17632–1764237535945 10.1021/jacs.3c03338
17. Lee SH Kim JM López-Álvarez M Imaging the bacterial cell wall using N-acetyl muramic acid-derived positron emission tomography radiotracers ACS Sensors 2023 8 12 4554 4565 10.1021/acssensors.3c01477 37992233
Lee SH, Kim JM, López-Álvarez M et al (2023) Imaging the bacterial cell wall using N-acetyl muramic acid-derived positron emission tomography radiotracers. ACS Sensors 8(12):4554–456537992233 10.1021/acssensors.3c01477
18. Lee IK Jacome DA Cho JK Imaging sensitive and drug-resistant bacterial infection with [11C]-trimethoprim J Clin Invest 2022 132 18 e156679 10.1172/JCI156679 36106638
Lee IK, Jacome DA, Cho JK et al (2022) Imaging sensitive and drug-resistant bacterial infection with [11C]-trimethoprim. J Clin Invest 132(18):e15667936106638 10.1172/JCI156679
19. Mota F Ordonez AA Firth G Radiotracer development for bacterial imaging J Med Chem 2020 63 1964 1977 10.1021/acs.jmedchem.9b01623 32048838
Mota F, Ordonez AA, Firth G et al (2020) Radiotracer development for bacterial imaging. J Med Chem 63:1964–197732048838 10.1021/acs.jmedchem.9b01623
20. Mutch CA Ordonez AA Qin H [11C]Para-aminobenzoic acid: a positron emission tomography tracer targeting bacteria specific metabolism ACS Infect Dis 2018 4 1067 1072 10.1021/acsinfecdis.8b00061 29712422
Mutch CA, Ordonez AA, Qin H et al (2018) [11C]Para-aminobenzoic acid: a positron emission tomography tracer targeting bacteria specific metabolism. ACS Infect Dis 4:1067–107229712422 10.1021/acsinfecdis.8b00061
21. Zhang Z Ordonez AA Wang H Positron emission tomography imaging with 2-[18F]F-p-aminobenzoic acid detects staphylococcus aureus infections and monitors drug response ACS Infect Dis 2018 4 1635 1644 10.1021/acsinfecdis.8b00182 30067329
Zhang Z, Ordonez AA, Wang H et al (2018) Positron emission tomography imaging with 2-[18F]F-p-aminobenzoic acid detects staphylococcus aureus infections and monitors drug response. ACS Infect Dis 4:1635–164430067329 10.1021/acsinfecdis.8b00182
22. Parker MFL López-Álvarez M Alanizi AA Evaluating the performance of pathogen-targeted positron emission tomography radiotracers in a rat model of vertebral discitis-osteomyelitis J Infect Dis 2023 228 S4 S281 S290 10.1093/infdis/jiad159 37788505
Parker MFL, López-Álvarez M, Alanizi AA et al (2023) Evaluating the performance of pathogen-targeted positron emission tomography radiotracers in a rat model of vertebral discitis-osteomyelitis. J Infect Dis 228(S4):S281–S29037788505 10.1093/infdis/jiad159
23. Ordonez AA Parker MFL Miller RJ 11C-Para-aminobenzoic acid PET imaging of S. aureus and MRSA infection in preclinical models and humans JCI Insight 2022 7 e154117 10.1172/jci.insight.154117 35014627
Ordonez AA, Parker MFL, Miller RJ et al (2022) 11C-Para-aminobenzoic acid PET imaging of S. aureus and MRSA infection in preclinical models and humans. JCI Insight 7:e15411735014627 10.1172/jci.insight.154117
24. Weinstein EA Ordonez AO Demarco VP Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography Sci Transl Med 2014 6 259 259ra146 10.1126/scitranslmed.3009815 25338757
Weinstein EA, Ordonez AO, Demarco VP et al (2014) Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography. Sci Transl Med 6(259):259ra14625338757 10.1126/scitranslmed.3009815
25. Ordonez AA Wintaco LM Mota F Imaging Enterobacterales infections in patients using pathogen-specific positron emission tomography Sci Transl Med 2021 13 eabe9805 10.1126/scitranslmed.abe9805 33853931
Ordonez AA, Wintaco LM, Mota F et al (2021) Imaging Enterobacterales infections in patients using pathogen-specific positron emission tomography. Sci Transl Med 13:eabe980533853931 10.1126/scitranslmed.abe9805
26. Du S Wey M Armstrong DW D-Amino acids in biological systems Chirality 2023 35 508 534 10.1002/chir.23562 37074214
Du S, Wey M, Armstrong DW (2023) D-Amino acids in biological systems. Chirality 35:508–53437074214 10.1002/chir.23562
27. Neumann KD Villanueva-Meyer JE Mutch CA Imaging active infection in vivo using D-amino acid derived PET radiotracers Sci Rep 2017 7 7903 10.1038/s41598-017-08415-x 28801560
Neumann KD, Villanueva-Meyer JE, Mutch CA et al (2017) Imaging active infection in vivo using D-amino acid derived PET radiotracers. Sci Rep 7:790328801560 10.1038/s41598-017-08415-x
28. Polvoy I Seo Y Parker M Imaging joint infections using D-methyl-11C-methionine PET/MRI: initial experience in humans Eur J Nucl Med Mol Imaging 2022 49 3761 3771 10.1007/s00259-022-05858-x 35732972
Polvoy I, Seo Y, Parker M et al (2022) Imaging joint infections using D-methyl-11C-methionine PET/MRI: initial experience in humans. Eur J Nucl Med Mol Imaging 49:3761–377135732972 10.1007/s00259-022-05858-x
29. Parker MFL Luu JM Schulte B Sensing living bacteria in vivo using D-alanine-derived 11C radiotracers ACS Cent Sci 2020 6 155 165 10.1021/acscentsci.9b00743 32123733
Parker MFL, Luu JM, Schulte B et al (2020) Sensing living bacteria in vivo using D-alanine-derived 11C radiotracers. ACS Cent Sci 6:155–16532123733 10.1021/acscentsci.9b00743
30. Renick PJ Mulgaonkar A Co CM Imaging of actively proliferating bacterial infections by targeting the bacterial metabolic footprint with D-[5-11C]-glutamine ACS Infectious Dis 2021 7 347 361 10.1021/acsinfecdis.0c00617
Renick PJ, Mulgaonkar A, Co CM et al (2021) Imaging of actively proliferating bacterial infections by targeting the bacterial metabolic footprint with D-[5-11C]-glutamine. ACS Infectious Dis 7:347–36110.1021/acsinfecdis.0c00617
31. Sorlin AM López-Alvarez M Biboy J Peptidoglycan-targeted [18F]3,3,3-trifluoro-d-alanine tracer for imaging bacterial infection JACS Au 2024 4 3 1039 1047 10.1021/jacsau.3c00776 38559735
Sorlin AM, López-Alvarez M, Biboy J et al (2024) Peptidoglycan-targeted [18F]3,3,3-trifluoro-d-alanine tracer for imaging bacterial infection. JACS Au 4(3):1039–104738559735 10.1021/jacsau.3c00776
32. Betts HM Milicevic Sephton S Tong C Synthesis, in vitro evaluation, and radiolabeling of fluorinated puromycin analogues: potential candidates for PET imaging of protein synthesis J Med Chem 2016 59 20 9422 9430 10.1021/acs.jmedchem.6b00968 27690460
Betts HM, Milicevic Sephton S, Tong C et al (2016) Synthesis, in vitro evaluation, and radiolabeling of fluorinated puromycin analogues: potential candidates for PET imaging of protein synthesis. J Med Chem 59(20):9422–943027690460 10.1021/acs.jmedchem.6b00968
33. Bourdier T Shepherd R Berghofer P Radiosynthesis and biological evaluation of L- and D-S-(3-[18F]fluoropropyl)homocysteine for tumor imaging using positron emission tomography J Med Chem 2011 54 1860 1870 10.1021/jm101513q 21351733
Bourdier T, Shepherd R, Berghofer P et al (2011) Radiosynthesis and biological evaluation of L- and D-S-(3-[18F]fluoropropyl)homocysteine for tumor imaging using positron emission tomography. J Med Chem 54:1860–187021351733 10.1021/jm101513q
34. Ellis R (n.d.) Hematoxylin and eosin (H&E) staining protocol. http://www.ihcworld.com/_protocols/special_stains/h&e_ellis.htm. Accessed 23 Nov 2022
35. Laverman P Boerman OC Corstens FHM Oyen WJG Fluorinated amino acids for tumour imaging with positron emission tomography Eur J Nucl Med 2002 29 5 681 690 10.1007/s00259-001-0716-y
Laverman P, Boerman OC, Corstens FHM, Oyen WJG (2002) Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med 29(5):681–69010.1007/s00259-001-0716-y
36. Prather KY O'Neal CM Westrup AM A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma Neurooncol Adv 2022 4 1 vdac008 35300149
Prather KY, O’Neal CM, Westrup AM et al (2022) A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma. Neurooncol Adv 4(1):vdac00835300149
37. Vollmer W Blanot D De Pedro MA Peptidoglycan structure and architecture FEMS Microbiol Rev 2008 32 2 149 167 10.1111/j.1574-6976.2007.00094.x 18194336
Vollmer W, Blanot D, De Pedro MA (2008) Peptidoglycan structure and architecture. FEMS Microbiol Rev 32(2):149–16718194336 10.1111/j.1574-6976.2007.00094.x
38. Yang D Kuang LR Cherif A Synthesis of [18F]fluoroalanine and [18F]fluorotamoxifen for imaging breast tumors J Drug Target 1993 1 259 267 10.3109/10611869308996084 8069568
Yang D, Kuang LR, Cherif A et al (1993) Synthesis of [18F]fluoroalanine and [18F]fluorotamoxifen for imaging breast tumors. J Drug Target 1:259–2678069568 10.3109/10611869308996084
39. Cava F De Pedro MA Lam H Davis BM Waldor MK Distinct pathways for modification of the bacterial cell wall by non-canonical D-amino acids EMBO J 2011 30 3442 3453 10.1038/emboj.2011.246 21792174
Cava F, De Pedro MA, Lam H, Davis BM, Waldor MK (2011) Distinct pathways for modification of the bacterial cell wall by non-canonical D-amino acids. EMBO J 30:3442–345321792174 10.1038/emboj.2011.246
40. Lupoli TJ Tsukamoto H Doud EH Transpeptidase-mediated incorporation of D-amino acids into bacterial peptidoglycan J Am Chem Soc 2011 133 10748 10751 10.1021/ja2040656 21682301
Lupoli TJ, Tsukamoto H, Doud EH et al (2011) Transpeptidase-mediated incorporation of D-amino acids into bacterial peptidoglycan. J Am Chem Soc 133:10748–1075121682301 10.1021/ja2040656
41. Caparrós M Pisabarro AG De Pedro MA Effect of D-amino acids on structure and synthesis of peptidoglycan in Escherichia coli J Bacteriol 1992 174 17 5549 5559 10.1128/jb.174.17.5549-5559.1992 1512190
Caparrós M, Pisabarro AG, De Pedro MA (1992) Effect of D-amino acids on structure and synthesis of peptidoglycan in Escherichia coli. J Bacteriol 174(17):5549–55591512190 10.1128/jb.174.17.5549-5559.1992
42. Kuru E Hughes HV Brown PJ In situ probing of newly synthesized peptidoglycan in live bacteria with fluorescent d-amino acids Angew Chem Int Ed 2012 51 12519 12523 10.1002/anie.201206749
Kuru E, Hughes HV, Brown PJ et al (2012) In situ probing of newly synthesized peptidoglycan in live bacteria with fluorescent d-amino acids. Angew Chem Int Ed 51:12519–1252310.1002/anie.201206749
43. Zhang C Reymond L Rutschmann O Fluorescent D-amino acids for super-resolution microscopy of the bacterial cell wall ACS Chem Biol 2022 17 2418 2424 10.1021/acschembio.2c00496 35994360
Zhang C, Reymond L, Rutschmann O et al (2022) Fluorescent D-amino acids for super-resolution microscopy of the bacterial cell wall. ACS Chem Biol 17:2418–242435994360 10.1021/acschembio.2c00496
44. Stewart MN Parker MFL Jivan S High enantiomeric excess in-loop synthesis of d-[methyl-11C]methionine for use as a diagnostic positron emission tomography radiotracer in bacterial infection ACS Infect Dis 2020 6 43 49 10.1021/acsinfecdis.9b00196 31697062
Stewart MN, Parker MFL, Jivan S et al (2020) High enantiomeric excess in-loop synthesis of d-[methyl-11C]methionine for use as a diagnostic positron emission tomography radiotracer in bacterial infection. ACS Infect Dis 6:43–4931697062 10.1021/acsinfecdis.9b00196
45. Xiong YQ Willard J Kadurugamuwa JL Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model Antimicrob Agents Chemother 2005 49 380 387 10.1128/AAC.49.1.380-387.2005 15616318
Xiong YQ, Willard J, Kadurugamuwa JL et al (2005) Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model. Antimicrob Agents Chemother 49:380–38715616318 10.1128/AAC.49.1.380-387.2005
46. European Centre for Disease Prevention and Control (n.d.) Survey of acute care hospitals in the EU/EAA (2011–2012). https://www.ecdc.europa.eu/en/healthcare-associated-infections-acute-care-hospitals/database/microorganisms-and-antimicrobial-resistance/most-frequent. Accessed 12 Oct 2022
47. Wilson WR Bower TC Creager MA Vascular graft infections, mycotic aneurysms, and endovascular infections. A scientific statement from the American Heart Association Circulation 2016 134 e412 e460 10.1161/CIR.0000000000000457 27737955
Wilson WR, Bower TC, Creager MA et al (2016) Vascular graft infections, mycotic aneurysms, and endovascular infections. A scientific statement from the American Heart Association. Circulation 134:e412–e46027737955 10.1161/CIR.0000000000000457
48. Tong SYC Davis JS Eichenberger E Holland TL Fowler VR Jr Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management Clin Microbiol Rev 2015 28 3 603 661 10.1128/CMR.00134-14 26016486
Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VR Jr (2015) Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28(3):603–66126016486 10.1128/CMR.00134-14
49. Schilcher K Horswill AR Staphylococcal biofilm development: structure, regulation, and treatment strategies Microbiol Mol Biol Rev 2020 84 3 e00026 e119 10.1128/MMBR.00026-19 32792334
Schilcher K, Horswill AR (2020) Staphylococcal biofilm development: structure, regulation, and treatment strategies. Microbiol Mol Biol Rev 84(3):e00026-e11932792334 10.1128/MMBR.00026-19
50. Heuker M Sijbesma JWA Aguilar Suárez R In vitro imaging of bacteria using 18F-fluorodeoxyglucose micro positron emission tomography Sci Rep 2017 7 4973 10.1038/s41598-017-05403-z 28694519
Heuker M, Sijbesma JWA, Aguilar Suárez R et al (2017) In vitro imaging of bacteria using 18F-fluorodeoxyglucose micro positron emission tomography. Sci Rep 7:497328694519 10.1038/s41598-017-05403-z
